Special Diabetes Program Reauthorization Act of 2025
Summary
The Special Diabetes Program Reauthorization Act of 2025 aims to extend funding for Special Diabetes Programs focusing on Type I diabetes research. The bill amends Section 330B(b)(2) of the Public Health Service Act to allocate $160,000,000 annually from 2026 through 2030. These funds will remain available until expended, ensuring continued support for diabetes research.
This reauthorization seeks to maintain the momentum in diabetes research and treatment. It directly addresses the need for ongoing funding to combat Type I diabetes.
The bill was introduced in the House of Representatives on September 18, 2025, and referred to the Committee on Energy and Commerce.
Expected Effects
The primary effect will be the continuation of funding for Special Diabetes Programs, specifically those focused on Type I diabetes. This will allow researchers and healthcare providers to maintain their efforts in finding better treatments and potential cures.
Without this reauthorization, these programs could face funding shortfalls, potentially hindering progress in diabetes research.
Potential Benefits
- Continued research into Type I diabetes, potentially leading to breakthroughs in treatment and prevention.
- Ensured funding stability for existing diabetes programs, allowing them to operate without interruption.
- Improved health outcomes for individuals with Type I diabetes through better access to care and innovative therapies.
- Potential reduction in long-term healthcare costs associated with diabetes management.
- Stimulation of the medical research sector, fostering innovation and job creation.
Most Benefited Areas:
Potential Disadvantages
- The bill allocates a significant amount of funding, potentially impacting other areas of healthcare or research.
- There may be concerns about the efficiency and effectiveness of the funded programs.
- The focus on Type I diabetes might divert resources from other important health issues.
- The bill does not address the root causes of diabetes, such as lifestyle factors and environmental influences.
- The allocated funds may not be sufficient to achieve significant progress in diabetes research.
Constitutional Alignment
The bill aligns with the general welfare clause of the US Constitution, which allows Congress to provide for the health and well-being of its citizens. The specific clause is found in the preamble: "promote the general Welfare".
Article I, Section 8 grants Congress the power to collect taxes and allocate funds for the common defense and general welfare of the United States. This bill falls under the umbrella of promoting general welfare by addressing public health concerns related to diabetes.
There are no apparent conflicts with specific constitutional amendments or limitations on congressional power.
Impact Assessment: Things You Care About ⓘ
This action has been evaluated across 19 key areas that matter to you. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).